(01)Overview
Retatrutide (LY3437943) is a single-molecule agonist of three incretin and metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its tri-receptor profile makes it a subject of active investigation in metabolic, energy-expenditure, and hepatic lipid research.
Published clinical-stage literature (e.g. Jastreboff et al., NEJM 2023) has examined retatrutide in the context of metabolic regulation; it remains an investigational compound and is not approved for any therapeutic use.
Each Darkside Labs vial is filled to a verified mass, lyophilized for stability, sealed under sterile conditions, and traceable to a batch Certificate of Analysis.
Research areas
- Metabolic & weight-regulation research



